BOTHELL, Wash and VANCOUVER, British Columbia, Aug. 16, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced initiation of the Cytisine Clinical Development Program. Cytisine is an established smoking cessation treatment that has been approved and marketed in…
/Read More
Strategic Collaboration with the National Institutes of Health (NIH) Instrumental in Facilitating IND-enabling Studies BOTHELL, Wash and VANCOUVER, British Columbia, Aug. 11, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for cytisine, an established smoking cessation treatment…
/Read More
Commences Trading on NASDAQ Capital Market on August 3, 2017 Under Ticker Symbol “ACHV” BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 1, 2017 — Achieve Life Sciences, Inc. (NASDAQ: ACHV) today announced the closing of its previously announced merger with OncoGenex Pharmaceuticals, as a result of which the stockholders of Achieve have become the majority…
/Read More
June 13, 2017 Special Meeting of OncoGenex Stockholders to Vote on Proposed Merger Scheduled for August 1, 2017 MILL VALLEY, Calif., BOTHELL, Wash. and VANCOUVER, British Columbia, June 13, 2017 /CNW/ — Achieve Life Sciences, Inc. (Achieve) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) (OncoGenex) today announced that the Registration Statement on Form S-4 has been…
/Read More
March 8, 2017 Professor Nancy Rigotti, MD, will chair a symposium entitled “Cytisine Update: Moving Research Forward Toward a Globally Affordable Tobacco Cessation Medication” Other presenters include Natalie Walker, PhD; David Shurtleff, PhD; SooHee Jeong, PhD; and Kamran Siddiqi, PhD. MILL VALLEY, Calif., BOTHELL, Wash. and VANCOUVER, British Columbia, March. 8, 2017 /PRNewswire/ — Achieve…
/Read More